HISTO, the first independent third-party pathology diagnostic center in China, recently announced the closing of its B round financing, raising over RMB 100 million. The round was led by Haier Medical with participation from Flyfot Ventures and other well-known life science funds. This Series B financing is the largest to date in the field of third-party pathology diagnosis, reflecting the capital market’s increasing confidence in the rapid technological development of the pathology industry. It is also signals further growth of technology-oriented leading enterprises and the professionalization of the pathology field.

CEC Capital Group served as the exclusive financial advisor for HISTO in this transaction.

As the first in China to obtain a license as an independent third-party pathology diagnostic center, HISTO has experienced rapid development in four key areas: clinical diagnostic services, standardized industrial services, digitalization and artificial intelligence support, and medical education media support. It is currently the only comprehensive institution in China capable of providing full pathology services and support.